AXCES Research Group, LLC. | Santa Fe, NM

Research site

(Unclaimed)

Location

531 Harkle Rd. Suite B, Santa Fe, New Mexico, United States of America

Site insights

Top conditions

Top treatments

Lenacapavir

Islatravir

Bictegravir

MK-4482

GS-1720

Molnupiravir

Bupropion Hydrochloride

MK-4482-002

GS-6207

PF-07321332

Parent organization

This site is a part of AXCES Research Group, LLC.

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

7 of 13 total trials

A Study to Learn About a COVID-19 Vaccine in Healthy Adults 50 Through 64 Years of Age

This study is designed to find out how well the COVID-19 vaccine protects people 50 to 64, who don't have any serious health problems, compared to a...

Active, not recruiting

COVID-19

SARS-COV-2 Infection

Biological: Placebo

Biological: BNT162b2 Vaccine

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE) (INFORMUS)

A randomized, double-blinded, placebo controlled study intended to capture cardiovascular outcomes during real-world use of naltrexone/bupropion (NB).

Active, not recruiting

Obesity

Drug: Placebo

Drug: Naltrexone-Bupropion (NB) Combination

Study Evaluating the Safety and Efficacy of Islatravir in Combination With Lenacapavir in Virologically Suppressed People With HIV

The primary objective of this study is to evaluate the efficacy of oral weekly islatravir (ISL) in combination with lenacapavir (LEN) in virologicall...

Active, not recruiting

HIV-1 Infection

Drug: ISL/LEN FDC

Drug: B/F/TAF

Study of Oral Weekly Lepetegravir (Formerly GS-1720) and Lenacapavir Pacfosacil (Formerly GS-4182) Versus Biktarvy in People With HIV-1 Who Are Virologically Suppressed (WONDERS1)

The goal of this clinical study is to learn more about the experimental drugs lepetegravir and lenacapavir pacfosacil; to compare the combination of...

Active, not recruiting

HIV-1-Infection

Drug: Lepetegravir

Drug: Lepetegravir/Lenacapavir pacfosacil FDC

Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (ISLEND-2)

The goal of this clinical study is to learn more about the safety and efficacy of switching to a once weekly tablet of islatravir/lenacapavir (ISL/LE...

Active, not recruiting

HIV-1-Infection

Drug: Antiretroviral Combinations

Drug: ISL/LEN

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With a Complicated Regimen (ARTISTRY-1)

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC) plus lenacapavir (LEN), versus...

Active, not recruiting

HIV-1-infection

Drug: Stable Baseline Regimen

Drug: Bictegravir

Study to Compare Bictegravir/Lenacapavir Versus Current Therapy in People With HIV-1 Who Are Successfully Treated With Biktarvy (ARTISTRY-2)

The goal of this clinical study is to learn more about the effects of switching to the study drugs, bictegravir (BIC)/lenacapavir (LEN), fixed-dose c...

Active, not recruiting

HIV-1-infection

Drug: B/F/TAF

Drug: Placebo to match B/F/TAF

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms